Skip to Content
Merck
CN
  • Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country.

Extensively drug-resistant tuberculosis: New Zealand's first case and the challenges of management in a low-prevalence country.

The Medical journal of Australia (2011-06-08)
Tze Liang Goh, Cindy R Towns, Katharine L Jones, Joshua T Freeman, Colin S Wong
ABSTRACT

In 2010, an immigrant from Burma was the first person to be diagnosed in New Zealand with extensively drug-resistant tuberculosis (XDR-TB). The strain of Mycobacterium tuberculosis is the most resistant reported to date in Australasia. Key difficulties of managing this disease in a low-prevalence country were delays from drug-susceptibility testing and in acquiring appropriate medicines, and a lack of evidence-based guidelines. Solutions are needed for New Zealand and the wider region as more cases of XDR-TB are likely to be encountered in the future.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Sodium 4-aminosalicylate dihydrate, ≥97.0% (T)
Sigma-Aldrich
4-Aminosalicylic acid, 99%
Sigma-Aldrich
4-Aminosalicylic acid, Vetec, reagent grade, 99%